Open-house biologics rebate agreement for aflibercept

Summary

The tender concerns an open-house biologics rebate agreement for the active substance aflibercept. It is an Open-House procedure in which all suitable pharmaceutical companies may join on uniform terms. No individual negotiations are held and no exclusivity is granted. The contract term is a maximum of 12 months starting on 01/12/2025 and ends no later than 30/11/2026. The detailed participation and contract conditions must be checked in the tender documents.